With more than 30 years’ experience in technical support and then sales in the cosmetics, toiletries and pharmaceutical packaging industries, Gannon joins Toolrite from German pharmaceutical organisation Uhlmann, where he held the role of sales manager for 10 years.
Gaining an HND in Mechanical & Production Engineering, Gannon further strengthened his technical expertise as sales engineer with Uhlmann agent, Ultrapac.
Toolrite appoints sales director
Steve Gannon takes newly formed position
You may also like
Finance
Ofichem acquires US drug substance CDMO Kinentia Biosciences to expand transatlantic network
The company has agreed to acquire New York-based Kinentia Biosciences, expanding its US presence and combining Kinentia’s early-stage development expertise with Ofichem’s European drug substance development and GMP manufacturing capabilities
Manufacturing
Patented device reinvents Solid Phase Extraction
Biotech Fluidics announce SPEedy - a device that provides an effortless way to perform Solid Phase Extraction (SPE) sample preparation procedures without need of an external vacuum and compatible with any adsorption chemistry or eluent composition
Manufacturing
Orano Med inaugurates Europe's first industrial-scale lead-212 radioligand therapy facility
The €29m ATLab site will target up to 10,000 doses annually and its two-hour proximity to major European airports meets the critical 24-hour production-to-administration window imposed by lead-212's 10.6-hour half-life
Manufacturing
Catalent launches ten-month gene-to-drug substance programme for complex biologics
The accelerated pathway extends the CDMO's Rapid Antibody framework to bispecifics and next-generation formats — targeting master cell bank release by month seven and bulk drug substance lot release by month ten
Design & Build
Sterling Pharma Solutions doubles ADC manufacturing capacity at Deeside with new GMP suite
The multi-million-pound expansion adds a 1400 sqft Grade C cleanroom, OEB5 containment handling and a 3400 sqft analytical laboratory — extending Sterling's bioconjugation capability from development through to Phase III and commercial scale